The role of allergen challenge chambers in the evaluation of anti‐allergic medication: an international consensus paper
暂无分享,去创建一个
G. Canonica | P. Cauwenberge | P. Lieberman | N. Krug | F. Horak | S. Quirce | S. Fineman | H. Takenaka | F. Leynadier | M. Briscoe | J. Day
[1] J. H. Day,et al. Experimental models for the evaluation of treatment of allergic rhinitis. , 2006, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[2] J. H. Day,et al. Comparative efficacy of cetirizine and fexofenadine for seasonal allergic rhinitis, 5-12 hours postdose, in the environmental exposure unit. , 2005, Allergy and asthma proceedings.
[3] F. Horak,et al. Levocetirizine has a longer duration of action on improving total nasal symptoms score than fexofenadine after single administration. , 2005, British journal of clinical pharmacology.
[4] W. Henderson,et al. The role of leukotrienes in allergic rhinitis. , 2005, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[5] G. Passalacqua,et al. Post‐marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[6] N. Krug,et al. Effect of loteprednol etabonate nasal spray suspension on seasonal allergic rhinitis assessed by allergen challenge in an environmental exposure unit , 2005, Allergy.
[7] M. Andersson,et al. Clinical trial design, nasal allergen challenge models, and considerations of relevance to pediatrics, nasal polyposis, and different classes of medication. , 2005, The Journal of allergy and clinical immunology.
[8] A. Day,et al. Factors affecting the allergic response to ragweed allergen challenge , 2005 .
[9] S. Durham,et al. Sublingual immunotherapy for allergic rhinitis: systematic review and meta‐analysis * , 2005, Allergy.
[10] Martinus Løvik,et al. The capacity of particles to increase allergic sensitization is predicted by particle number and surface area, not by particle mass. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.
[11] I. Vukušič,et al. Variation in ragweed (Ambrosia artemisiifolia L.) pollen concentration in central Croatia, 2002-2003. , 2004, Annals of agricultural and environmental medicine : AAEM.
[12] I. Finegold. Immunotherapy in the age of anti-IgE , 2004, Clinical reviews in allergy & immunology.
[13] S. Burastero,et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. , 2004, The Journal of allergy and clinical immunology.
[14] R. Berkowitz,et al. Fexofenadine HCl 60 mg/ pseudoephedrine HCl 120 mg has a 60-minute onset of action in the treatment of seasonal allergic rhinitis symptoms, as assessed in an allergen exposure unit. , 2004, Allergy and asthma proceedings.
[15] J. Bousquet,et al. The ARIA/EAACI criteria for antihistamines: an assessment of the efficacy, safety and pharmacology of desloratadine , 2004, Allergy.
[16] F. Horak,et al. A direct comparison of the efficacy of antihistamines in SAR and PAR: randomised, placebo-controlled studies with levocetirizine and loratadine using an environmental exposure unit – the Vienna Challenge Chamber (VCC) , 2004, Current medical research and opinion.
[17] K. Hörmann,et al. Changes in daytime sleepiness, quality of life, and objective sleep patterns in seasonal allergic rhinitis: a controlled clinical trial. , 2004, The Journal of allergy and clinical immunology.
[18] C. Pashos,et al. Economic impact and quality-of-life burden of allergic rhinitis , 2004, Current medical research and opinion.
[19] E. Levetin,et al. Correlation of environmental factors with asthma and rhinitis symptoms in Tulsa, OK. , 2004, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[20] W. Greisner. Onset of action for the relief of allergic rhinitis symptoms with second-generation antihistamines. , 2004, Allergy and asthma proceedings.
[21] Y. Lau,et al. Increasing prevalence of allergic rhinitis but not asthma among children in Hong Kong from 1995 to 2001 (Phase 3 International Study of Asthma and Allergies in Childhood) , 2004, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.
[22] J. H. Day,et al. Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the Environmental Exposure Unit (EEU) , 2004, International journal of clinical practice.
[23] H. Malling,et al. Clinical efficacy of sublingual and subcutaneous birch pollen allergen‐specific immunotherapy: a randomized, placebo‐controlled, double‐blind, double‐dummy study , 2004, Allergy.
[24] Soo Cheng,et al. Pollen counts in relation to the prevalence of allergic rhinoconjunctivitis, asthma and atopic eczema in the International Study of Asthma and Allergies in Childhood (ISAAC) , 2003, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[25] N. Krug,et al. Validation of an environmental exposure unit for controlled human inhalation studies with grass pollen in patients with seasonal allergic rhinitis , 2003, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[26] D. Bernstein,et al. Key pollen allergens in North America. , 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[27] R. Puy,et al. Allergen immunotherapy for asthma. , 2003, The Cochrane database of systematic reviews.
[28] R. Kane,et al. A comparison of the effect of diphenhydramine and desloratadine on vigilance and cognitive function during treatment of ragweed-induced allergic rhinitis. , 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[29] S. Spector,et al. Symptom severity assessment of allergic rhinitis: part 1. , 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[30] W. Berger. Overview of allergic rhinitis. , 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[31] A. Harris,et al. Comparison of the effects of desloratadine 5‐mg daily and placebo on nasal airflow and seasonal allergic rhinitis symptoms induced by grass pollen exposure , 2003, Allergy.
[32] J. Bousquet,et al. Requirements for medications commonly used in the treatment of allergic rhinitis , 2003, Allergy.
[33] F. Horak,et al. Decongestant Activity of Desloratadine in Controlled-Allergen-Exposure Trials , 2002 .
[34] Robert Kane,et al. Decrements in vigilance and cognitive functioning associated with ragweed-induced allergic rhinitis. , 2002, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[35] T. Yagami. Allergies to Cross-Reactive Plant Proteins , 2002, International Archives of Allergy and Immunology.
[36] J. Weiler,et al. Onset of action, efficacy, and safety of fexofenadine 60 mg/pseudoephedrine 120 mg versus placebo in the Atlanta allergen exposure unit. , 2002, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[37] A. Harris,et al. Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. , 2002, The Journal of allergy and clinical immunology.
[38] S. Willsie. Improved strategies and new treatment options for allergic rhinitis , 2002, The Journal of the American Osteopathic Association.
[39] K. Baba,et al. [Clinical efficacy of Ebastine under placebo-controlled outdoors clinical study on cedar pollinosis]. , 2002, Arerugi = [Allergy].
[40] R. Leurs,et al. H1‐antihistamines: inverse agonism, anti‐inflammatory actions and cardiac effects , 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[41] Erkka Valovirta,et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). , 2002, The Journal of allergy and clinical immunology.
[42] J. A. Grant,et al. A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. , 2002, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[43] B. Kramer,et al. Comparative onset of action and symptom relief with cetirizine, loratadine, or placebo in an environmental exposure unit in subjects with seasonal allergic rhinitis: confirmation of a test system. , 2001, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[44] R. Naclerio,et al. Superiority of an intranasal corticosteroid compared with an oral antihistamine in the as-needed treatment of seasonal allergic rhinitis. , 2001, Archives of internal medicine.
[45] F. Horak,et al. Efficacy and Safety of an Oral Formulation of Cetirizine and Prolonged-release Pseudoephedrine versus Xylometazolin Nasal Spray in Nasal Congestion , 2001, Arzneimittelforschung.
[46] J. Bousquet,et al. A revised nomenclature for allergy: An EAACI position statement from the EAACI nomenclature task force , 2001, Allergy.
[47] F. Horak,et al. Controlled Comparison of the Efficacy and Safety of Cetirizine 10 mg o.d. and Fexofenadine 120 mg o.d. in Reducing Symptoms of Seasonal Allergic Rhinitis , 2001, International Archives of Allergy and Immunology.
[48] A. Ellis,et al. Quality of life indices may be predictive of placebo and medication response to treatment for allergic rhinitis. , 2001, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[49] M. Laaidi. Forecasting the start of the pollen season of Poaceæ: evaluation of some methods based on meteorological factors , 2001, International journal of biometeorology.
[50] F. Horak,et al. Efficacy and Tolerability of Intranasally Applied Dimetindene Maleate Solution versus Placebo in the Treatment of Seasonal Allergic Rhinitis , 2000, Arzneimittelforschung.
[51] E. Juniper,et al. Quality of life in patients with allergic rhinitis. , 2000, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[52] H. Burge,et al. Outdoor allergens. , 2000, Environmental health perspectives.
[53] A. Coste. [ENT diseases associated with allergic rhinitis: a review of the literature]. , 2000, Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Societe d'oto-laryngologie des hopitaux de Paris.
[54] D. Frenz. Interpreting atmospheric pollen counts for use in clinical allergy: spatial variability. , 2000, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[55] J. Weiler,et al. Onset-of-action for antihistamine and decongestant combinations during an outdoor challenge. , 2000, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[56] A. Ellis,et al. Onset of action of intranasal budesonide (Rhinocort aqua) in seasonal allergic rhinitis studied in a controlled exposure model. , 2000, The Journal of allergy and clinical immunology.
[57] C. Bachert,et al. Guidelines for nasal provocations with aspects on nasal patency, airflow, and airflow resistance. International Committee on Objective Assessment of the Nasal Airways, International Rhinologic Society. , 2000, Rhinology.
[58] G. Passalacqua,et al. Post‐marketing surveillance study on the safety of sublingual immunotherapy in pediatric patients , 1999, Allergy.
[59] E Lesaffre,et al. A note on the number needed to treat. , 1999, Controlled clinical trials.
[60] J. H. Day,et al. Environmental exposure unit: a system to test anti-allergic treatment. , 1999, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[61] A. Ellis,et al. Impact on quality of life during an allergen challenge research trial. , 1999, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[62] Howarth. Assessment of antihistamine efficacy and potency , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[63] R. Settipane. Complications of allergic rhinitis. , 1999, Allergy and asthma proceedings.
[64] A. Harris,et al. Mometasone furoate nasal spray is rapidly effective in the treatment of seasonal allergic rhinitis in an outdoor (park), acute exposure setting. , 1999, Allergy and asthma proceedings.
[65] J. Bousquet. Rapid symptom relief in rhinitis , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[66] F. Horak,et al. Environmental priming influences allergen‐specific nasal reactivity , 1998, Allergy.
[67] I. Farooqi,et al. Early childhood infection and atopic disorder , 1998, Thorax.
[68] N. Jones,et al. The prevalence of allergic rhinosinusitis: a review , 1998, The Journal of Laryngology & Otology.
[69] S. Fineman,et al. Executive Summary of Joint Task Force Practice Parameters on Diagnosis and Management of Rhinitis. , 1998, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[70] S. Spector,et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. , 1998, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[71] F. Horak,et al. Efficacy and safety relative to placebo of an oral formulation of cetirizine and sustained‐release pseudoephedrine in the management of nasal congestion , 1998, Allergy.
[72] Giorgio Walter Canonica,et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases , 1998 .
[73] S. Bonini,et al. Pollen‐related allergy in Europe * , 1998, Allergy.
[74] M. Briscoe,et al. Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: effects after controlled ragweed pollen challenge in an environmental exposure unit. , 1998, The Journal of allergy and clinical immunology.
[75] F. Horak,et al. Immunotherapy with sublingual birch pollen extract. A short-term double-blind placebo study. , 1998, Journal of investigational allergology & clinical immunology.
[76] F. Horak,et al. Dose-dependent protection by azelastine eye drops against pollen-induced allergic conjunctivitis. A double-blind, placebo-controlled study. , 1998, Arzneimittel-Forschung.
[77] G. Canonica,et al. Allergen-Specific Nasal Challenge: Response Kinetics of Clinical and Inflammatory Events to Rechallenge , 1998, International Archives of Allergy and Immunology.
[78] S. Jäger,et al. Effect of continuous allergen challenge on clinical symptoms and mediator release in dust‐mite‐allergic patients , 1998, Allergy.
[79] J. H. Day,et al. Onset of action, efficacy, and safety of a single dose of fexofenadine hydrochloride for ragweed allergy using an environmental exposure unit. , 1997, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[80] M. Trakultivakorn,et al. Skin prick reaction and nasal provocation response in diagnosis of nasal allergy to the house dust mite. , 1997, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[81] J. H. Day,et al. Onset of action and efficacy of terfenadine, astemizole, cetirizine, and loratadine for the relief of symptoms of allergic rhinitis. , 1997, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[82] S. Rønborg,et al. Exposure chamber for allergen challenge. A placebo‐controlled, double‐blind trial in house‐dust‐mite asthma , 1997, Allergy.
[83] E. Monroe,et al. Appraisal of the validity of histamine-induced wheal and flare to predict the clinical efficacy of antihistamines. , 1997, The Journal of allergy and clinical immunology.
[84] G. Canonica,et al. Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: an antiallergic activity. , 1996, The Journal of allergy and clinical immunology.
[85] L. Reece,et al. Intranasal fluticasone propionate inhibits recovery of chemokines and other cytokines in nasal secretions in allergen-induced rhinitis. , 1996, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[86] S. Jäger,et al. Efficacy and tolerability of astemizole-D and Loratadine-D during prolonged, controlled allergen challenge in the Vienna Challenge Chamber. , 1996, Arzneimittel-Forschung.
[87] R. Nathan. Changing strategies in the treatment of allergic rhinitis. , 1996, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[88] F Horak,et al. Quantification of conjunctival vascular reaction by digital imaging. , 1996, The Journal of allergy and clinical immunology.
[89] F. Horak,et al. Efficacy of intranasally applied dimethindene maleate solution as spray in adult volunteers with symptoms of seasonal allergic rhinitis in the Vienna challenge chamber. , 1996, Arzneimittel-Forschung.
[90] J. H. Day,et al. Efficacy of immunotherapy to ragweed antigen tested by controlled antigen exposure. , 1996, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[91] J. H. Day,et al. A randomized, double-blind, placebo-controlled, controlled antigen delivery study of the onset of action of aerosolized triamcinolone acetonide nasal spray in subjects with ragweed-induced allergic rhinitis. , 1996, The Journal of allergy and clinical immunology.
[92] T. Casale,et al. Speed of onset of action of Tilarin , 1996, Allergy.
[93] S. Rønborg,et al. Exposure chamber for allergen challenge The development and validation of a new concept , 1996, Allergy.
[94] J. Weiler,et al. Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis. , 1996, The Journal of allergy and clinical immunology.
[95] L. Reece,et al. Secretion of chemokines and other cytokines in allergen-induced nasal responses: inhibition by topical steroid treatment. , 1995, American journal of respiratory and critical care medicine.
[96] T. Casale,et al. The leukotriene D4-receptor antagonist, ICI 204,219, relieves symptoms of acute seasonal allergic rhinitis. , 1995, American journal of respiratory and critical care medicine.
[97] L. Juhlin. A comparison of the pharmacodynamics of H1‐receptor antagonists as assessed by the induced wheal‐and‐flare model , 1995, Allergy.
[98] G. Canonica,et al. Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early- and late-phase reactions after allergen-specific challenge. , 1995, The Journal of allergy and clinical immunology.
[99] C. Bindslev‐Jensen,et al. Efficacy of acrivastine in the treatment of allergic rhinitis during natural pollen exposure: onset of action , 1994, Allergy.
[100] F. Horak,et al. Controlled exposure to mite allergen for a dose-finding of dimethindene maleate (DMM) , 1994, Agents and Actions.
[101] C. Sherbourne,et al. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. , 1994 .
[102] F. Horak,et al. Pharmacodynamic dose finding of dimetindene in a sustained release formulation. , 1993, Arzneimittel-Forschung.
[103] A. Pécoud,et al. Facial thermography during nasal provocation tests with histamine and allergen , 1993, Allergy.
[104] S. Jäger,et al. Effects of H1‐receptor antagonists on nasal obstruction in atopic patients , 1993, Allergy.
[105] S. Holgate,et al. The comparative actions and adverse effect profile of single doses of H1-receptor antihistamines in the airways and skin of subjects with asthma. , 1993, The Journal of allergy and clinical immunology.
[106] T. Casale,et al. Nedocromil sodium is rapidly effective in the therapy of seasonal allergic rhinitis. , 1993, The Journal of allergy and clinical immunology.
[107] R. Einarsson,et al. Mite (Der p 1, Der f 1) and cat (Fel d 1) allergens in the homes of babies with a family history of allergy , 1993, Allergy.
[108] S. Spector. The placebo effect is nothing to sneeze at. , 1992, The Journal of allergy and clinical immunology.
[109] F. Horak,et al. Onset and Duration of the Effects of Three Antihistamines in Current Use – Astemizole, Loratadine and Terfenadine Forte – Studied during Prolonged, Controlled Allergen Challenges in Volunteers , 1992, The Journal of international medical research.
[110] G. Guyatt,et al. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis , 1991, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[111] H. Pross,et al. Immunologic studies of subjects with asthma exposed to formaldehyde and urea-formaldehyde foam insulation (UFFI) off products. , 1987, The Journal of allergy and clinical immunology.
[112] M. Chapman,et al. Seasonal variation in dust mite and grass-pollen allergens in dust from the houses of patients with asthma. , 1987, The Journal of allergy and clinical immunology.
[113] H. Burge,et al. Allergen carriage by atmospheric aerosol. II. Ragweed-pollen determinants in submicronic atmospheric fractions. , 1984, The Journal of allergy and clinical immunology.
[114] E. Levetin,et al. Weather patterns and ragweed pollen production in Tulsa, Oklahoma. , 1982, Annals of allergy.
[115] Connell Jt. A novel method to assess antihistamine and decongestant efficacy. , 1979 .
[116] S. Freedman,et al. Double‐blind trial comparing flunisolide and placebo for the treatment of perennial rhinitis , 1978, Clinical allergy.
[117] E. Arnáiz,et al. Effects of rupatadine vs placebo on allergen-induced symptoms in patients exposed to aeroallergens in the Vienna Challenge Chamber. , 2006, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[118] B. Samoliński,et al. Correlation between conjunctival provocation test results and conjunctival symptoms in pollinosis - preliminary report. , 2005, Annals of agricultural and environmental medicine : AAEM.
[119] F. Horak,et al. Efficacy and Safety of an Oral Formulation of Cetirizine and Prolonged-Release Pseudoephedrine versus Budesonide Nasal Spray in the Management of Nasal Congestion in Allergic Rhinitis , 2005, Treatments in respiratory medicine.
[120] J. H. Day,et al. Randomized double-blind comparison of cetirizine and fexofenadine after pollen challenge in the Environmental Exposure Unit: duration of effect in subjects with seasonal allergic rhinitis. , 2004, Allergy and asthma proceedings.
[121] C. Naspitz,et al. Nasal provocation test (NPT) with isolated and associated dermatophagoides pteronyssinus (Dp) and endotoxin lipopolysaccharide (LPS) in children with allergic rhinitis (AR) and nonallergic controls. , 2004, Journal of investigational allergology & clinical immunology.
[122] J. Weiler,et al. Efficacy and safety of clemastine-pseudoephedrine-acetaminophen versus pseudoephedrine-acetaminophen in the treatment of seasonal allergic rhinitis in a 1-day, placebo-controlled park study. , 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[123] F. Horak,et al. Efficacy and Safety of Ketotifen Eye Drops as Adjunctive Therapy to Mometasone Nasal Spray in Subjects with Seasonal Allergic Rhinoconjunctivitis , 2003, Clinical drug investigation.
[124] S. Weinstein. Combination therapy in the treatment of allergic rhinitis. , 2002, Allergy and asthma proceedings.
[125] C. Arendt,et al. Efficacy and safety of levocetirizine in seasonal allergic rhinitis. , 2001, Acta oto-rhino-laryngologica Belgica.
[126] D. Nash,et al. Optimizing quality of care and cost effectiveness in treating allergic rhinitis in a managed care setting. , 2000, The American journal of managed care.
[127] J. Bousquet,et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. , 1998, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[128] F. Horak,et al. Dose-related control of allergic rhinitis symptoms by a H1-receptor antagonist. Finding the proper doses [correction of dosis] of dimethindene maleate in patients with allergic rhinitis. , 1994, International archives of allergy and immunology.
[129] T Shida,et al. Measurement of allergens associated with dust mite allergy. II. Concentrations of airborne mite allergens (Der I and Der II) in the house. , 1989, International archives of allergy and applied immunology.
[130] G. Guyatt,et al. A comparison of Likert and visual analogue scales for measuring change in function. , 1987, Journal of chronic diseases.
[131] J. T. Connell. A novel method to assess antihistamine and decongestant efficacy. , 1979, Annals of allergy.
[132] J. T. Connell. Quantitative intranasal pollen challenges. 3. The priming effect in allergic rhinitis. , 1969, The Journal of allergy.